Form 4: Vigil Neuroscience's Chief Science Officer, David L.F. Gray, Granted Stock Options

David L.F. Gray, Chief Science Officer of Vigil Neuroscience, Inc., was granted stock options to purchase 125,000 shares of common stock on March 1, 2024.

Summary

• On March 1, 2024, David L.F. Gray, the Chief Science Officer of Vigil Neuroscience, Inc., was granted stock options.
• The stock options allow Gray to purchase 125,000 shares of Vigil Neuroscience's common stock at an exercise price of $3.39 per share.
• The options were granted under the company's 2021 Stock Option and Incentive Plan.
• The options vest in 48 equal monthly installments, beginning on April 1, 2024, and expire on March 1, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral to slightly positive indicator.

Positives

• The granting of stock options to the Chief Science Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Vigil Neuroscience.
• Companies such as BioNTech, Moderna, and Novavax also utilize stock options to incentivize their key personnel.
• The vesting schedule of 48 months is typical for such grants, aligning with industry norms for long-term retention.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Science Officer to drive company success.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates